Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events
- PMID: 15837230
- DOI: 10.1016/j.vaccine.2005.01.089
Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events
Abstract
Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged > or =60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.
Similar articles
-
Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).Vaccine. 2014 Oct 7;32(44):5769-75. doi: 10.1016/j.vaccine.2014.08.051. Epub 2014 Sep 3. Vaccine. 2014. PMID: 25192973 Review.
-
Review of the risks and benefits of yellow fever vaccination including some new analyses.Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Expert Rev Vaccines. 2012. PMID: 22551029 Review.
-
Adverse event reports following yellow fever vaccination.Vaccine. 2008 Nov 11;26(48):6077-82. doi: 10.1016/j.vaccine.2008.09.009. Epub 2008 Sep 20. Vaccine. 2008. PMID: 18809449
-
Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.Am J Trop Med Hyg. 2006 Aug;75(2):333-6. Am J Trop Med Hyg. 2006. PMID: 16896144
-
Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93. MMWR Morb Mortal Wkly Rep. 2002. PMID: 12455906
Cited by
-
Advancing molecular modeling and reverse vaccinology in broad-spectrum yellow fever virus vaccine development.Sci Rep. 2024 May 12;14(1):10842. doi: 10.1038/s41598-024-60680-9. Sci Rep. 2024. PMID: 38735993 Free PMC article.
-
Living with HIV and Getting Vaccinated: A Narrative Review.Vaccines (Basel). 2023 Apr 25;11(5):896. doi: 10.3390/vaccines11050896. Vaccines (Basel). 2023. PMID: 37243000 Free PMC article. Review.
-
Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.J Travel Med. 2023 Nov 18;30(7):taad037. doi: 10.1093/jtm/taad037. J Travel Med. 2023. PMID: 37000007 Free PMC article.
-
Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD.Vaccines (Basel). 2023 Feb 15;11(2):445. doi: 10.3390/vaccines11020445. Vaccines (Basel). 2023. PMID: 36851322 Free PMC article.
-
Yellow Fever Vaccine-Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil.Emerg Infect Dis. 2023 Mar;29(3):493-500. doi: 10.3201/eid2903.220989. Emerg Infect Dis. 2023. PMID: 36823036 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
